Kontigo Care: Well-positioned to meet the demand for immediate drug detection - Redeye

Redeye reiterates its valuation following the Q2 2024 report, which was stronger than our expectations overall. Given the challenging macro climate, the business performed well, accompanied by solid cost control. The outlook remains cautiously optimistic in the short term. However, we are confident about the potential of the newly launched Previct Drug and Previct Safety, which have garnered significant attention both in Sweden and internationally, as well as from adjacent sectors.

Länk till analysen i sin helhet: https://www.redeye.se/research/1016984/kontigo-care-well-positioned-to-meet-the-demand-for-immediate-drug-detection?utm_source=finwire&utm_medium=RSS